A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Clinical Trial to Assess Safety, Tolerability, and Pharmacokinetics of LY-CovMab, a Potent Human Neutralizing Antibody Against SARS-CoV-2

INTRODUCTION: We aimed to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of a single dose of LY-CovMab in Chinese healthy adults. METHODS: We conducted a phase 1, randomized, dose-escalation, placebo-controlled trial in 42 volunteers, 18–45 years of age, and 40 out of 42 rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qian, Zhou, Renpeng, Yang, Jingjing, Dou, Changlin, Gan, Tianyi, Liu, Fujia, Hu, Baihui, Song, Deyong, Lu, Chao, Hu, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651971/
https://www.ncbi.nlm.nih.gov/pubmed/34878625
http://dx.doi.org/10.1007/s40121-021-00572-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651971/
https://www.ncbi.nlm.nih.gov/pubmed/34878625
http://dx.doi.org/10.1007/s40121-021-00572-x

Ejemplares similares